Blue Jet Healthcare (BLUEJET) investor relations material

Executive summary

• Q1 FY27 revenue and profit declined YoY despite QoQ recovery, led by PI & API traction as intermediate supply resumed after customer inventory normalization.

• Growth plans center on manufacturing expansion, R&D capabilities and a broader CDMO platform; QIP proceeds support strategic investment.

Financial highlights

• Revenue from operations was ₹2,931.13m, up 24.9% QoQ and down 17.4% YoY; total income was ₹3,083.50m.

• EBITDA was ₹981m, up 37.6% QoQ and down 18.9% YoY; PAT was ₹782.64m, up 21.6% QoQ and down 14.2% YoY.

• PI sales were ₹1,210m versus ₹2,120m in Q1 FY26, contributing to the YoY revenue decline.

• Other operating income of ₹15.5 crore was primarily linked to byproduct sales and product mix, particularly higher API activity.

Outlook and guidance

• API order visibility is strong for the next 3–4 quarters; FY27 performance in the molecule affected by customer destocking is expected to be sustained.

• FY27 plans include launching three contrast media candidates and beginning pilot activities for a new high-intensity sweetener.

• Four chronic-therapy programs are progressing in customer development; two high-conviction NCE opportunities may advance initially with small validation or clinical quantities.

• Vizag commercialization is expected from end-FY29 to FY30, with ramp-up potentially extending to FY31–FY32.

• Strategy includes capacity expansion, R&D investment, operational efficiency, supply-chain resilience and advanced contrast media intermediates.